

Zydus receives FDA nod for Morphine Sulfate Tablets

02 July 2015 | News | By BioSpectrum Bureau

Zydus receives FDA nod for Morphine Sulfate Tablets



Zydus Group has received the final approval from the United States Food and Drug administration (USFDA) to market its Morphine Sulfate ER Tablets, used in the treatment of chronic pain or cancer related pain.

The Tablets will be manufactured by Neshor Pharmaceuticals, located at St.Louis, USA, the company said in a filing to the BSE.

Neshor Pharmaceuticals is a subsidiary of Zydus Pharmaceuticals.